Diaspora led pharma gets grant for research against Parkinson's

In particular, the owners of Kannalife, Thoma Kikis and Dean Petkanas, presented the preclinical research project of the therapeutic KLS-13019, investigating its effect on neuroinflammation and mitochondrial dysfunction, which are involved in the disease of Parkinson's disease (PD).

The research is coordinated by the pharmacologist Dr. Douglas Brenneman, who, in his official statements published by the company, expressed his joy for the satisfaction of the request, but also his optimism for the course and results of the investigation, against the background of dealing with of Parkinson's disease.

“We are honored to receive this support from the Michael J. Fox Foundation, a leading organization dedicated to accelerating the development of improved treatments for Parkinson's disease. We are confident that we can make substantial progress toward this goal and ultimately improve the lives of patients living with Parkinson's disease,” noted Brenneman.

In the same vein, the deputy director of Research Programs at the Michael J. Fox Foundation, Dr. Jessica Tome Garcia, spoke about the expectations for the results of the research that Kannalife will conduct.

“We look forward to seeing the results of Kannalife Sciences' innovative work on KLS-13019. This funding underscores the Foundation's dedication to advancing therapeutic research for Parkinson's disease by addressing neuroinflammation and mitochondrial dysfunction, two key drivers of the disease,” Dr. Garcia emphasized.

At the same time, Dr. Brenneman expressed his thanks to the staff and management of Kannalife, making special mention of Dean Petkana, for his contribution and belief in the prospects of the research